Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06076837 · ClinicalTrials.gov registry record · Phase 1

The Seven Trial: Exploiting the Unfolded Protein Response

A Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic, sponsored by HonorHealth Research Institute.

Compiled by PlainTrial · August 8, 2026

Active
Registry status: Phase 1
Development phase: 6
Enrollment target: 1
Study location

NCT06076837: Active Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic, sponsored by HonorHealth Research Institute.

NCT06076837 is a Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 6 participants, below the 131-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06076837, a Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic, is active but no longer recruiting, sponsored by HonorHealth Research Institute.

ACTIVE NOT RECRUITING
Registry status: Phase 1
Development phase: 6 participants
Enrollment target: 1
Study location

Study Summary

The goal of this investigator initiated interventional study is to improve the response to the anticancer treatments (chemotherapy) in people who have previously untreated metastatic pancreas cancer. The main question it aims to answer is: • Do new types of immune-based therapies, called botensilimab, and balstilimab, when given in combination with chemotherapy consisting of nab-paclitaxel + gemcitabine + cisplatin, and oral medications of chloroquine and celecoxib help patients with previously untreated metastatic pancreatic cancer? Participants will be administered two immune-based therapies: * Botensilimab (also referred to as AGEN1811) * Balstilimab (also referred to as AGEN2034) Patients will be evaluated when given in combination with: * Triple chemotherapy (nab-paclitaxel + gemcitabine + cisplatin), plus two oral medications: * chloroquine * celecoxib

Primary Outcome

To determine the maximum tolerated dose (MTD) of botensilimab when given in combination with balstilimab + triplet chemotherapy regimen (consisting of nab-paclitaxel + gemcitabine + cisplatin) + chloroquine + celecoxib to be used in Part 2-Dose Expansion. MTD will be defined at the dose of botensilimab at which no more than 1 of 6 evaluable patients experiences a dose-limiting toxicity (DLT).

Conditions Studied

Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG Celecoxib
DRUG Balstilimab
DRUG Nab paclitaxel
DRUG Botensilimab
DRUG Chloroquine Phosphate

Study Locations (1)

Arizona

Clinical Trials Nurse Navigator - Scottsdale

Trial Details

Field	Value
Enrollment Target	6 participants
Start Date	2025-01-09
Est. Completion	2026-12
Phase	Phase 1

HonorHealth Research Institute

20 total trials

What the registry record for NCT06076837 still lists

NCT06076837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 131-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Pancreatic Cancer Metastatic appearing as the primary indexed condition, and to 5 interventions - of which Celecoxib is the first listed.

NCT06076837 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT06076837 about?

NCT06076837 is a clinical study titled "The Seven Trial: Exploiting the Unfolded Protein Response". The goal of this investigator initiated interventional study is to improve the response to the anticancer treatments (chemotherapy) in people who have previously untreated metastatic pancreas cancer. The main question it aims to answer is: • Do new types of immune-based therapies, called botensilim...

What is the current status of trial NCT06076837?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-01-09. Estimated completion is 2026-12.

What conditions does trial NCT06076837 study?

This clinical trial studies the following conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic.

What interventions are being tested in trial NCT06076837?

The interventions under investigation include: Celecoxib (DRUG), Balstilimab (DRUG), Nab paclitaxel (DRUG), Botensilimab (DRUG), Chloroquine Phosphate (DRUG).

Who is sponsoring clinical trial NCT06076837?

This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06076837 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06076837's enrollment target sits among peer trials

6 10th of 9 the lowest of 9 other Pancreatic Cancer Metastatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06076837, the US trial registry maintained by the National Library of Medicine. NCT06076837 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.